Trial Profile
Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria (CSU)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Sep 2018
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- 04 Jul 2017 New trial record